Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target

Benzinga Newsdesk www.benzinga.com Positive 75.9%

Neg 0% Neu 0% Pos 75.9%

Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.